Picture of Chimerix logo

CMRX — Chimerix News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Chimerix Inc expected to post a loss of 24 cents a share - Earnings Preview

* Chimerix Inc  CMRX.OQ   CMRX.O  is expected to show a fall
in
quarterly revenue when it reports  results on February 29 for
the period ending December 31 2023
    * The Durham North Carolina-based  company is expected to
report a
92.6% decrease in revenue to $60 thousand from $814 thousand a
year ago, according to the mean estimate from 7 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Chimerix Inc is for a
loss
of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chimerix
Inc is
$7.00​, above​ its last closing price of $1.19. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.22       -0.23      -0.27     Missed  -18
 Jun. 30 2023  -0.23       -0.24      -0.21     Beat    13.8
 Mar. 31 2023  -0.25       -0.25      -0.24     Beat    4.1​
 Dec. 31 2022  -0.24       -0.24      -0.24     Met     -1.4
 ​​Sep.        2.13        2.14       2.75      Beat    28.6
 30 2022                                                
 Jun. 30 2022  -0.25       -0.24      -0.27     Missed  -11.6​
 Mar. 31 2022  -0.33       -0.33      -0.28     Beat    15.6
 Dec. 31 2021  -0.32       -0.17      -0.45     Missed  -157.1
 This summary was machine generated February 27 at 17:22 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Chimerix

See all news